Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Inhibrx's ozekibart posts 63% tumour response in Ewing sarcoma, opening a second FDA conversation

Early-stage data on the DR5 agonist with chemotherapy could widen the drug's potential commercial footprint beyond chondrosarcoma, though no filing plan has been disclosed.

17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news

Inhibrx Biosciences has given investors and clinicians a fresh look at how ozekibart performs in a second rare bone and soft-tissue cancer, and said it will take the findings to US regulators. The drug is already the subject of an accepted biologics licence application in conventional chondrosarcoma, so any move into Ewing sarcoma would add to a pipeline that currently rests heavily on one asset.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Inhibrx Biosciences, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →